Strik, Herwig Matthias

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T11:08:46Z"],["dc.date.available","2018-11-07T11:08:46Z"],["dc.date.issued","2008"],["dc.format.extent","1115"],["dc.identifier.isi","000261695800218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52865"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Duke Univ Press"],["dc.publisher.place","Durham"],["dc.relation.conference","8th Congress of the European-Association-for-Neuro-Oncology (EANO)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","1522-8517"],["dc.title","LONG TERM STABILIZATION OF LEPTOMENINGEAL AND SOLID CNS METASTASES FROM BREAST CANCER WITH COMBINED INTRATHECAL LIPOSOMAL ARA-C AND SYSTEMIC TEMOZOLOMIDE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","863"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Molecular Medicine Reports"],["dc.bibliographiccitation.lastpage","867"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Buhk, J.-H."],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Christmann, M."],["dc.contributor.author","Kaina, Bernd"],["dc.date.accessioned","2018-11-07T11:09:39Z"],["dc.date.available","2018-11-07T11:09:39Z"],["dc.date.issued","2008"],["dc.description.abstract","Treatment of recurrent malignant glioma, which has a poor patient prognosis, has not been standardised. Moreover, it is unclear whether repeated treatment with temozolomide is effective in patients who received previous temozolomide treatment before developing a recurrence. Here, we present the results of a high-dose individually adapted 21-day regimen demonstrating that rechallenge is effective even in patients expressing O(6)-methylguanine-DNA methyltransferase (MGMT) in the tumor. Twenty-one patients with recurrent malignant gliomas pre-treated with temozolomide, 18 WHO IV glioblastoma (GBM) and 3 WHO III patients, received 100 mg/m(2) temozolomide on days 1-21/28. The GBM patients had a median Karnofsky performance status of 60% and a median age of 54.8 years. Blood counts decreased continuously, enabling a gradual dose adaptation. When blood counts dropped below normal values, temozolomide was applied on days 1-5/7. Dosage was reduced to 50-75 mg/m(2) in 11 patients and gradually increased up to 130 mg/m(2) in 3 patients. WHO grade 3/4 toxicity was hematological in 3 patients and non-hematological in 3 patients. In GBM patients (n=18), response after >3 months was complete in 3 patients, partial in 1 (22%), stable disease in 7 (39%) and progressive disease in 7 (39%). Progression-free survival at 6 months (PFS-6M) was 39%. Median survival was 9.1 months from relapse and 17.9 months overall. Of the patients with unmethylated MGMT promoter, 2/7 were progression-free for >6 (15 and 19) months. The data indicate that rechallenge with near-continuous, higher-dose temozolomide (100 mg/m(2) on days 1-21/28 or days 1-5/7 with individual dose adaptation) is also feasible in patients with critical blood counts. Objective responses can be achieved even after relapse during a conventional 5/28-day regimen. The resistance of tumors"],["dc.description.sponsorship","[DFG-KA724]"],["dc.identifier.doi","10.3892/mmr_00000042"],["dc.identifier.isi","000261058300016"],["dc.identifier.pmid","21479498"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53056"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1791-2997"],["dc.title","Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","71"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","72"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Giese, A. ."],["dc.contributor.author","Bock, C."],["dc.contributor.author","Baehr, M."],["dc.date.accessioned","2018-11-07T11:18:51Z"],["dc.date.available","2018-11-07T11:18:51Z"],["dc.date.issued","2008"],["dc.identifier.isi","000253372800226"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55134"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Rechallenge of malignant gliomas with temozolomide - Can it be effective?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Bock, C."],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Marosi, Christine"],["dc.contributor.author","Kaiser, U."],["dc.contributor.author","Christmann, M."],["dc.contributor.author","Kaina, Bernd"],["dc.date.accessioned","2018-11-07T11:08:46Z"],["dc.date.available","2018-11-07T11:08:46Z"],["dc.date.issued","2008"],["dc.format.extent","1062"],["dc.identifier.isi","000261695800017"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52864"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Duke Univ Press"],["dc.publisher.place","Durham"],["dc.relation.conference","8th Congress of the European-Association-for-Neuro-Oncology (EANO)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","1522-8517"],["dc.title","TEGWONDO-DEVELOPMENT OF A NOVEL NEAR-CONTINUOUS DOSE-DENSE TEMOZOLOMIDE REGIMEN FOR THE TREATMENT OF RECURRENT GLIOMAS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T11:18:51Z"],["dc.date.available","2018-11-07T11:18:51Z"],["dc.date.issued","2008"],["dc.format.extent","72"],["dc.identifier.isi","000253372800227"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55135"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Long term stabilization of leptomeningeal and solid CNS metastases from breast cancer with combined intrathecal liposomal ARA-C and systemic temozolomide"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5191"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","5195"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T11:21:15Z"],["dc.date.available","2018-11-07T11:21:15Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: Patients with neoplastic meningitis (NM) from breast cancer have a median survival of 4-8 months with specific treatment. Here, good tolerance and long-term stabilization with combined intrathecal liposomal cytarabine (Ara-C), which is probably the most promising drug for intrathecal chemotherapy to date, near-continuous temozolomide and radiotherapy is reported in two patients with leptomeningeal and solid central nervous system (CNS) mefastases from breast cancer. Case Reports: A 42- and a 43-year-old female presented with NM and disseminated CNS metastases from human epidermal growth factor receptor type 2 (Het-2)-positive breast cancer. After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7. Cerebrospinal fluid (CSF) cytology and neurological symptoms improved in both patients and stabilized for several months. The patients survived 10 and 17 months after diagnosis of NM, without signs of neurological toxicity. Conclusion: Intensive treatment is complicated by extensive pre-treatment and the lack of active CNS-penetrating systemic drugs. The long-term results with up to 17 intrathecal injections of liposomal AraC show that this treatment regimen is feasible and well-tolerated. The stabilization of both patients indicates activity of this combined intrathecal and systemic regimen that is based on long-term exposure of the tumour cells to both Ara-C and temozolomide. The results need to be confirmed prospectively."],["dc.identifier.isi","000273365700040"],["dc.identifier.pmid","20044635"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55730"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Int Inst Anticancer Research"],["dc.relation.issn","0250-7005"],["dc.title","Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-term Intrathecal Liposomal Ara-C Combined with Dose-dense Temozolomide"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Eckermann, K."],["dc.contributor.author","Baehr, M."],["dc.contributor.author","Weishaupt, Jochen H."],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T11:08:47Z"],["dc.date.available","2018-11-07T11:08:47Z"],["dc.date.issued","2008"],["dc.format.extent","1143"],["dc.identifier.isi","000261695800334"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52869"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Duke Univ Press"],["dc.publisher.place","Durham"],["dc.relation.conference","8th Congress of the European-Association-for-Neuro-Oncology (EANO)"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","1522-8517"],["dc.title","Inhibition of Cyclin-Dependent Kinases by Roscovitine Induces Suppression of Proliferation and Migration in Human Glioma Cells"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Bock, C."],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Marosi, Christine"],["dc.contributor.author","Kaiser, U."],["dc.contributor.author","Christmann, M."],["dc.contributor.author","Kaina, Bernd"],["dc.contributor.author","Baehr, M."],["dc.date.accessioned","2018-11-07T11:15:03Z"],["dc.date.available","2018-11-07T11:15:03Z"],["dc.date.issued","2008"],["dc.identifier.isi","000208457400551"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54284"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","0732-183X"],["dc.title","Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]